...
首页> 外文期刊>Antiviral therapy >Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression.
【24h】

Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression.

机译:通过CCR5沉默保护免受原代CD4 T细胞的HIV-1感染,对于整个CCR5表达都是有效的。

获取原文
获取原文并翻译 | 示例

摘要

Stable gene silencing by RNA interference (RNAi) can be achieved by expression of small hairpin RNAs (shRNAs) from RNA polymerase III promoters. We have tested lentiviral vectors expressing shRNAs targetting CCR5 in primary CD4 T cells from donors representing various CCR5 and CCR2 genetic backgrounds covering the full spectrum of CCR5 expression levels and permissiveness for HIV-1 infection. A linear decrease in CCR5 expression resulted in a logarithmic decrease in cellular infection, giving up to three logs protection from HIV-1 infection in vitro. Protection was maintained at very high multiplicity of infection. This and other recent reports on RNAi should open a debate about the use of RNAi gene therapy for HIV infection.
机译:通过表达来自RNA聚合酶III启动子的小发夹RNA(shRNA),可以实现通过RNA干扰(RNAi)稳定的基因沉默。我们已经测试了慢病毒载体,该慢病毒载体在来自代表各种CCR5和CCR2遗传背景的供体的原代CD4 T细胞中表达靶向CCR5的shRNA,该背景涵盖了CCR5表达水平的全谱和对HIV-1感染的允许性。 CCR5表达的线性下降导致细胞感染的对数下降,从而在体外对HIV-1感染提供了多达三个对数保护。在很高的感染复数下保持保护。有关RNAi的本报告和其他近期报告应就使用RNAi基因疗法治疗HIV感染展开一场辩论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号